JSPR — Jasper Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $68.33m
- $28.82m
Annual income statement for Jasper Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 20.7 | 36.8 | 51.2 | 68.9 | 76.2 |
| Operating Profit | -20.7 | -36.8 | -51.2 | -68.9 | -76.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -31.7 | -30.6 | -37.7 | -64.5 | -71.3 |
| Net Income After Taxes | -31.7 | -30.6 | -37.7 | -64.5 | -71.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -31.7 | -30.6 | -37.7 | -64.5 | -71.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -31.7 | -30.6 | -37.7 | -64.5 | -71.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.37 | -8.09 | -10.3 | -6.18 | -4.89 |